Skip to main content
JOHNSON & JOHNSON logo

JOHNSON & JOHNSON — Investor Relations & Filings

Listed
Ticker · JNJ ISIN · US4781601046 LEI · 549300G0CFPGEF6X2043 US Manufacturing
Open in API
Filings indexed 3,142 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country US United States of America
Listing US JNJ · 20 venues

About JOHNSON & JOHNSON

https://www.jnj.com/

Johnson & Johnson is a healthcare company that operates through two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division is focused on the research, development, and delivery of new treatments for complex diseases in areas such as oncology, immunology, neuroscience, and cardiopulmonary conditions. The MedTech segment develops and provides a broad portfolio of medical technologies and solutions. It innovates in fields including surgery, orthopaedics, vision, and interventional solutions, aiming to create smarter, less invasive, and more personalized healthcare treatments. The company's mission is to address significant health challenges through science-based innovation at the intersection of biology and technology.

Recent filings

Filing Released Lang Actions
SD
Regulatory Filings Classification · 92% confidence The document is an SEC Form SD (“Specialized Disclosure Report”) related to conflict minerals disclosure for the reporting period, which is a specific regulatory filing. It is not an annual report, earnings release, or other listed category but rather a standardized SEC compliance filing. Thus, it falls under the fallback category Regulatory Filings (RNS).
2026-05-27 English
Regulatory Filings 2026
Regulatory Filings
2026-05-13 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-05-01 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a Form 8-K Current Report filed with the SEC by Johnson & Johnson. The key content is the submission of matters to a vote of security holders at the 2026 Annual Meeting, including election of directors, approval of executive compensation, ratification of appointment of the auditing firm, and a shareholder proposal result. The focus is on reporting the official voting results from the shareholder meeting. This aligns with the category Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting such as Annual General Meetings (AGM). The document is not a full report like an Annual Report or Interim Report, nor is it a proxy solicitation or governance information. The length supports it being a substantive voting results report rather than a brief announcement or regulatory filing. Therefore, the best classification is DVA with high confidence.
2026-04-27 English
10-Q - JOHNSON & JOHNSON (0000200406) (Filer)
Interim / Quarterly Report Q1 2026
2026-04-22 English
8-K - JOHNSON & JOHNSON (0000200406) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC by Johnson & Johnson, dated April 14, 2026. It announces the company's sales and earnings for the first quarter ended March 29, 2026, and also announces a dividend increase. The document includes press releases and supplementary sales data but does not contain the full financial statements or detailed financial analysis itself. The length is 4441 characters, which is relatively short and consistent with an announcement rather than a full report. The document is primarily an announcement of quarterly earnings results and dividend declaration, typical of an Earnings Release (ER).
2026-04-14 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.